Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2016

22.09.2016 | Original Article

Cleavage of E-Cadherin Contributes to Defective Barrier Function in Neosquamous Epithelium

verfasst von: Thomas M. Runge, Nicholas J. Shaheen, Zorka Djukic, Suzanne Hallquist, Roy C. Orlando

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

After ablation of Barrett’s esophagus (BE), the esophagus heals with neosquamous epithelium (NSE). Despite normal endoscopic appearance, NSE exhibits defective barrier function with similarities to defects noted in the distal esophageal epithelium in patients with gastroesophageal reflux disease (GERD).

Aim

To determine whether patients with NSE, unlike patients with healthy esophageal epithelium, have C-terminal fragments (CTFs) of e-cad detectable on tissue biopsy. Secondly, to determine whether patients with NSE have elevated levels of N-terminal fragments (NTFs) of e-cad in the serum.

Methods

Fifteen patients with ablated long-segment BE, who had healing with formation of NSE, were enrolled in this pilot study. Western blots for CTFs and NTFs were performed on biopsies of NSE. Venous blood was obtained to assess levels of NTFs. Endoscopic distal esophageal biopsies from patients without esophageal disease served as tissue controls. Control blood samples were obtained from healthy subjects.

Results

Blots of NSE were successful in 14/15 patients, and all 14 (100 %) had a 35-kD CTF of e-cad, while CTFs were absent in healthy control tissues. Despite CTFs in NSE, serum NTFs of e-cad in NSE were similar to controls, p > 0.05. However, unlike healthy controls, blots of NSE also showed NTFs with molecular weights of 70–90 kD.

Conclusions

Cleavage of e-cad, as evidenced by the presence of CTFs and NTFs on biopsy, contributes to defective barrier function in NSE. However, unlike findings reported in GERD patients, serum NTFs are not elevated in NSE patients. This difference may reflect poor absorption with tissue entrapment of NTFs in previously ablated areas with poorly perfused NSE.
Literatur
2.
Zurück zum Zitat Spechler SJ. Barrett’s esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Med Clin N Am. 2002;86:1423–1445.CrossRefPubMed Spechler SJ. Barrett’s esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Med Clin N Am. 2002;86:1423–1445.CrossRefPubMed
3.
Zurück zum Zitat Spechler SJ. Barrett’s esophagus. In: Orlando RC, ed. Gastroesophageal Reflux Disease. New York, NY: CRC Press; 2000:219–258.CrossRef Spechler SJ. Barrett’s esophagus. In: Orlando RC, ed. Gastroesophageal Reflux Disease. New York, NY: CRC Press; 2000:219–258.CrossRef
4.
Zurück zum Zitat Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461–467.CrossRefPubMed Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461–467.CrossRefPubMed
5.
Zurück zum Zitat Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.CrossRefPubMed Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677.CrossRefPubMed
6.
Zurück zum Zitat Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: An endoscopic study. Gastroenterology. 2005;129:1825–1831.CrossRefPubMed Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: An endoscopic study. Gastroenterology. 2005;129:1825–1831.CrossRefPubMed
7.
Zurück zum Zitat Ward EM, Wolfsen HC, Achem SR, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101:12–17.CrossRefPubMed Ward EM, Wolfsen HC, Achem SR, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101:12–17.CrossRefPubMed
8.
Zurück zum Zitat Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. Jama. 2002;287:1972–1981.CrossRefPubMed Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. Jama. 2002;287:1972–1981.CrossRefPubMed
9.
Zurück zum Zitat Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMed Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMed
10.
Zurück zum Zitat Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–468.CrossRefPubMedPubMedCentral Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–468.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Lyday W, Corbett F, Kuperman D, et al. Radiofrequency ablation of Barrett’s esophagus: Outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010;42:272–278.CrossRefPubMed Lyday W, Corbett F, Kuperman D, et al. Radiofrequency ablation of Barrett’s esophagus: Outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010;42:272–278.CrossRefPubMed
13.
Zurück zum Zitat Pouw RE, Gondrie JJ, Rygiel AM, et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am J Gastroenterol. 2009;104:1366–1373.CrossRefPubMed Pouw RE, Gondrie JJ, Rygiel AM, et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am J Gastroenterol. 2009;104:1366–1373.CrossRefPubMed
14.
Zurück zum Zitat Herrero LA, Pouw RE, Van Vilsteren FG, et al. What are the outcomes of endoscopic radiofrequency ablation for very long segments of Barrett esophagus containing neoplasia? Gastrointest Endosc. 2009;69:AB116. Herrero LA, Pouw RE, Van Vilsteren FG, et al. What are the outcomes of endoscopic radiofrequency ablation for very long segments of Barrett esophagus containing neoplasia? Gastrointest Endosc. 2009;69:AB116.
15.
Zurück zum Zitat Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.CrossRefPubMed Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.CrossRefPubMed
16.
Zurück zum Zitat Jovov B, Shaheen NJ, Orlando GS, et al. Defective barrier function in neosquamous epithelium. Am J Gastroenterol. 2013;108:386–391.CrossRefPubMed Jovov B, Shaheen NJ, Orlando GS, et al. Defective barrier function in neosquamous epithelium. Am J Gastroenterol. 2013;108:386–391.CrossRefPubMed
17.
Zurück zum Zitat Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12:1840–1847.CrossRefPubMedPubMedCentral Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12:1840–1847.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Vaccaro BJ, Gonzalez S, Poneros JM, et al. Detection of intestinal metaplasia after successful eradication of Barrett’s esophagus with radiofrequency ablation. Dig Dis Sci. 2011;56:1996–2000.CrossRefPubMedPubMedCentral Vaccaro BJ, Gonzalez S, Poneros JM, et al. Detection of intestinal metaplasia after successful eradication of Barrett’s esophagus with radiofrequency ablation. Dig Dis Sci. 2011;56:1996–2000.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: Results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86.CrossRefPubMedPubMedCentral Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: Results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–1206.CrossRefPubMed Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57:1200–1206.CrossRefPubMed
21.
Zurück zum Zitat Basu K, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: Factors determining persistence and recurrence of Barrett’s epithelium. Gut. 2002;51:776–780.CrossRefPubMedPubMedCentral Basu K, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: Factors determining persistence and recurrence of Barrett’s epithelium. Gut. 2002;51:776–780.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Michopoulos S, Tsibouris P, Bouzakis H, et al. Complete regression of Barrett’s esophagus with heat probe thermocoagulation: Mid-term results. Gastrointest Endosc. 1999;50:165–172.CrossRefPubMed Michopoulos S, Tsibouris P, Bouzakis H, et al. Complete regression of Barrett’s esophagus with heat probe thermocoagulation: Mid-term results. Gastrointest Endosc. 1999;50:165–172.CrossRefPubMed
23.
Zurück zum Zitat Haag S, Nandurkar S, Talley NJ. Regression of Barrett’s esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc. 1999;50:229–240.CrossRefPubMed Haag S, Nandurkar S, Talley NJ. Regression of Barrett’s esophagus: the role of acid suppression, surgery, and ablative methods. Gastrointest Endosc. 1999;50:229–240.CrossRefPubMed
24.
Zurück zum Zitat Tobey N, Hosseini S, Argote C, et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol. 2004;99:13–22.CrossRefPubMed Tobey N, Hosseini S, Argote C, et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol. 2004;99:13–22.CrossRefPubMed
25.
Zurück zum Zitat Orlando R. Pathophysiolgoy of gastroesophageal reflux disease: Esophageal epithelial resistance. In: Castell DORJ, ed. The Esophagus. 4th ed. Philadelphia: Williams & Wilkins; 2004:421–433. Orlando R. Pathophysiolgoy of gastroesophageal reflux disease: Esophageal epithelial resistance. In: Castell DORJ, ed. The Esophagus. 4th ed. Philadelphia: Williams & Wilkins; 2004:421–433.
26.
Zurück zum Zitat Tobey NA, Carson JL, Alkiek RA, et al. Dilated intercellular spaces: A morphological feature of acid reflux–damaged human esophageal epithelium. Gastroenterology. 1996;111:1200–1205.CrossRefPubMed Tobey NA, Carson JL, Alkiek RA, et al. Dilated intercellular spaces: A morphological feature of acid reflux–damaged human esophageal epithelium. Gastroenterology. 1996;111:1200–1205.CrossRefPubMed
27.
Zurück zum Zitat Jovov B, Que J, Tobey NA, et al. Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1039–1047.CrossRefPubMedPubMedCentral Jovov B, Que J, Tobey NA, et al. Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1039–1047.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Alvaro-Villegas J, Sobrino-Cossio S, Hernandez-Guerrero A, et al. Dilated intercellular spaces in subtypes of gastroesophagic reflux disease. Rev Esp Enferm Dig Organo Of Soc Esp Patol Dig. 2010;102:302–307. Alvaro-Villegas J, Sobrino-Cossio S, Hernandez-Guerrero A, et al. Dilated intercellular spaces in subtypes of gastroesophagic reflux disease. Rev Esp Enferm Dig Organo Of Soc Esp Patol Dig. 2010;102:302–307.
29.
Zurück zum Zitat Moulton DE, Crandall W, Lakhani R, et al. Expression of a novel cadherin in the mouse and human intestine. Pediatr Res. 2004;55:927–934.CrossRefPubMed Moulton DE, Crandall W, Lakhani R, et al. Expression of a novel cadherin in the mouse and human intestine. Pediatr Res. 2004;55:927–934.CrossRefPubMed
30.
Zurück zum Zitat Jamora C, Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat Cell Biol. 2002;4:E101–E108.CrossRefPubMed Jamora C, Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat Cell Biol. 2002;4:E101–E108.CrossRefPubMed
31.
Zurück zum Zitat Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997;13:119–146.CrossRefPubMed Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997;13:119–146.CrossRefPubMed
32.
Zurück zum Zitat Guo X, Rao JN, Liu L, et al. Regulation of adherens junctions and epithelial paracellular permeability: A novel function for polyamines. Am J Physiol Cell Physiol. 2003;285:C1174–C1187.CrossRefPubMed Guo X, Rao JN, Liu L, et al. Regulation of adherens junctions and epithelial paracellular permeability: A novel function for polyamines. Am J Physiol Cell Physiol. 2003;285:C1174–C1187.CrossRefPubMed
33.
Zurück zum Zitat Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta (BBA) Biomembr. 2008;1778:660–669.CrossRef Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta (BBA) Biomembr. 2008;1778:660–669.CrossRef
34.
Zurück zum Zitat Herzog C, Haun RS, Ludwig A, et al. ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A. J Biol Chem. 2014;289:13308–13322.CrossRefPubMedPubMedCentral Herzog C, Haun RS, Ludwig A, et al. ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A. J Biol Chem. 2014;289:13308–13322.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Huovila A-PJ, Turner AJ, Pelto-Huikko M, et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci. 2005;30:413–422.CrossRefPubMed Huovila A-PJ, Turner AJ, Pelto-Huikko M, et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci. 2005;30:413–422.CrossRefPubMed
36.
Zurück zum Zitat Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci USA. 2005;102:9182–9187.CrossRefPubMedPubMedCentral Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci USA. 2005;102:9182–9187.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Orlando RC. The integrity of the esophageal mucosa. Balance between offensive and defensive mechanisms. Best Practice & Research Clinical. Gastroenterology. 2010;24:873–882. Orlando RC. The integrity of the esophageal mucosa. Balance between offensive and defensive mechanisms. Best Practice & Research Clinical. Gastroenterology. 2010;24:873–882.
38.
Zurück zum Zitat Kahaleh M, Van Laethem J-L, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett’s esophagus treated by argon plasma coagulation and acid suppression. Endoscopy. 2002;34:950–955.CrossRefPubMed Kahaleh M, Van Laethem J-L, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett’s esophagus treated by argon plasma coagulation and acid suppression. Endoscopy. 2002;34:950–955.CrossRefPubMed
39.
Zurück zum Zitat Yeh R, Gerson L, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus*. Dis Esophagus. 2003;16:193–198.CrossRefPubMed Yeh R, Gerson L, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus*. Dis Esophagus. 2003;16:193–198.CrossRefPubMed
40.
Zurück zum Zitat Gerson L, Boparai V, Ullah N, et al. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett’s oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004;20:637–643.CrossRefPubMed Gerson L, Boparai V, Ullah N, et al. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett’s oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004;20:637–643.CrossRefPubMed
41.
Zurück zum Zitat Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett’s esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol. 2006;101:1964–1971.CrossRefPubMed Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett’s esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol. 2006;101:1964–1971.CrossRefPubMed
Metadaten
Titel
Cleavage of E-Cadherin Contributes to Defective Barrier Function in Neosquamous Epithelium
verfasst von
Thomas M. Runge
Nicholas J. Shaheen
Zorka Djukic
Suzanne Hallquist
Roy C. Orlando
Publikationsdatum
22.09.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4315-y

Weitere Artikel der Ausgabe 11/2016

Digestive Diseases and Sciences 11/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.